Value for money?

A recent report compared the costs of newer anti-diabetic medications.  This included glitazones, exenatide and gliptins.  The cheapest of these costs about £400 a year per patient compared with under £10 for a sulphonylurea and under £20 for metformin.

The two important questions are :

1.  Are the newer medications 20 times as good as metformin?
2.  Is it better, purely on a cost basis, to treat twenty people with metformin or one person with a gliptin?


Related Articles

8th December 2011

Trial & Error?

Once again, the thorny issue of drug licensing has arisen.  The two sides to the question have been drawn up in lines...

Read More

5th March 2013

That Helsinki Feeling

Linda Goldie, one of our Clinical Directors, is in Helsinki at the moment. Here’s what she’s up to:...

Read More

30th January 2014

A dose of your own medicine

One of our friends is in the terminal phase of cancer. He was suffering quite a lot of pain so he was seen by one of...

Read More